Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European Medicines Agency Jan 27, 2023 10:46 HKT/SGT Read More
エーザイとバイオジェン、抗アミロイドβプロトフィブリル抗体「レカネマブ」について早期アルツハイマー病に係る販売承認申請が欧州医薬品庁により受理 Jan 27, 2023 08:30 JST Read More
Cantor Fitzgerald Initiates Coverage on Prenetics with "Overweight" Rating Jan 26, 2023 12:16 HKT/SGT Read More
Eisai Commences Business Activities at New Pharma Sales Subsidiary in Israel Jan 19, 2023 09:35 HKT/SGT Read More
Eisai Listed as a Global 100 Most Sustainable Corporation for The Seventh Time Highest Ranked Global Pharmaceutical Company Jan 19, 2023 08:07 HKT/SGT Read More
Eisai Aims to Advance Gastrointestinal Cancer Treatment with Research Across Multiple Tumor Types at ASCO GI 2023 Jan 18, 2023 12:28 HKT/SGT Read More
Eisai Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer's Disease in Japan Jan 16, 2023 17:56 HKT/SGT Read More
Soligenix On Track to Deliver Important Front-Line Treatment to US Market in 2024 Jan 16, 2023 06:00 HKT/SGT Read More
American Green (OTC:ERBB) Architectural Plans for Its 40,000 s.f. Cypress Chill Cannabis Grow are in the Final Review Phase Jan 13, 2023 09:00 HKT/SGT Read More
Novotech Acquires US-based Drug Development Consulting Firm, CBR International Jan 12, 2023 15:00 HKT/SGT Read More